Journavx for Pain Management: Toward Affordabil...

By Rene Pretorius

April 25, 2025

In this review I summarize the ICER 2025 evaluation report of suzetrigine (Journavx®), a new FDA-approved non-opioid oral analgesic. It targets the N...
FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough i...
Advancing Pediatric Leukemia Trial: Precision Medicine and Transformative Res...
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...
Neoadjuvant Immunotherapy Efficacy: Enhancing Treatment Strategies for Head a...
NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatment...
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Engineering Resilience: Mastering Pharma Patent Expiration Strategy
Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefit...
Oral Health in Africa: Promoting Collaborative Solutions
Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implic...
Advances in Colorectal Cancer Screening: Access and Cost